Drugs / Debio 0123
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05815160 | May 2023 → Mar 2026 | small cell lung carcinoma | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 1 | NCT05109975 | Nov 2021 → Apr 2026 | cancer | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 1 | NCT04855656 | Apr 2021 → Dec 2027 expected | neoplasm | Debiopharm International SA | Recruiting | No outcome recorded |
| Phase 1 | NCT03968653 | Jul 2019 → Oct 2025 | cancer | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06612203 | Jan 2025 → Feb 2027 expected | breast cancer | MedSIR | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05765812 | May 2023 → Sep 2028 expected | IDH-wildtype glioblastoma, grade III glioma | Debiopharm International SA | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Debio0123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04855656 ↗ |
| Action | Inhibit | “Oral WEE1 Inhibitor” NCT04855656 ↗ |
| Route | Oral | “given as an oral capsule” NCT03968653 ↗ |
| Target | WEE1 | “Oral WEE1 Inhibitor” NCT04855656 ↗ |